ACR Convergence - American College of Rheumatology Convergence

Using data and bioinformatics could hold the key to numerous treatment options.

Anti-tumor necrotic factor drugs could help delay hip deterioration in patients with ankylosing spondylitis.

Patients who live with rheumatoid arthritis do not die from swollen joints but face twice the risk of suffering a heart attack or stroke.

Telehealth broadly is about creating care connections across boundaries, care that encourages patients’ independence, prevention and wellness; and care that can be leveraged for needed interventions. If we get telehealth right we can reduce impact of what we know is a growing health workforce shortage and concurrently create a healthier, more engaged patient base.

The 12-biomarker test is gaining acceptance among rheumatologists and was recently added to a clinical guideline.

Be careful what you wish for: SGR and FFS will be models of the past; the success of the APM and MIPS will rely on compensation, collaboration and participation; and, to date, much remains to be done in the development of quality-based payment reform under MACRA.

New therapeutic targets provide hope for targeted treatments for rheumatoid diseases.

JAK inhibitors may be more effective than older biologic drugs in certain patients.

New data from studies of multiple drugs highlights Janssen’s commitment to rheumatic diseases.

Pfizer will highlight successes of Xeljanz at ACR/ARHP annual meeting.

Amgen will present findings from clinical studies of both branded and investigational drugs.